US3046196A - Therapeutic compositions - Google Patents

Therapeutic compositions Download PDF

Info

Publication number
US3046196A
US3046196A US815276A US81527659A US3046196A US 3046196 A US3046196 A US 3046196A US 815276 A US815276 A US 815276A US 81527659 A US81527659 A US 81527659A US 3046196 A US3046196 A US 3046196A
Authority
US
United States
Prior art keywords
composition
gram
skin
present
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US815276A
Other languages
English (en)
Inventor
Vaulchier Dorothy De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CRAIG PHARMACEUTICAL Co I
CRAIG PHARMACEUTICAL COMPANY Inc
Original Assignee
CRAIG PHARMACEUTICAL Co I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CRAIG PHARMACEUTICAL Co I filed Critical CRAIG PHARMACEUTICAL Co I
Priority to US815276A priority Critical patent/US3046196A/en
Priority to FR828198A priority patent/FR618M/fr
Application granted granted Critical
Publication of US3046196A publication Critical patent/US3046196A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof

Definitions

  • compositions useful in the treatment of certain diseases of human beings and also useful in the treatment of certain diseases of animals are provided which, when applied in various Ways to the skin of the patient being treated, result in dramatic amelioration of such diseased conditions as osteoarthritis, rheumatoid arthritis, bursitis, myositis, spastic muscles, post traumatic rheumatic diseases, tenosynovitis and torticollis.
  • the present invention is of benefit in the treatment of diseases characterized by inflammation of osseous, cartilaginous or fibrous con- Beneficial results have also been obtained in the treatment of sinusitis and certain defects of vision.
  • the present invention comprises a mixture of ingredients none of which when used individually is capable of producing the response obtained by the combination.
  • compositions of the present invention comprise the following ingredients in approximately the following proportions:
  • Phenol About 30 grams. Glycerine About 4 milliliters. Water About 1 milliliter. Citric acid From about 0.1 to about 0.5 gram. Sodium salicylate From about 0.1 to
  • the preferred concentration of citric acid in the above formulation is approximately 0.3 gram, and the preferred concentration of sodium. salicylate in the above formula tion is also about 0.3 gram. It will be understood that the proportions are subject to some variation. It must be emphasized, however, that the relative proportions are an essential feature of the present invention, and material alteration of the proportions results in loss of the desired therapeutic properties. No special procedure is required to prepare the composition of the present invention. It should be noted that the final composition is in the liquid state. By the use of the formulations of the present invention, it is possible to obtain for the first time clear, colorless, stable solutions of phenol crystals in exceedingly small amounts of liquid.
  • Solutions of phenol known prior to the present invention contain considerably larger amounts of solvents, and in addition the previously known solutions had the disadvantage of becoming discolored and crystallizing relatively rapidly.
  • the influence of light and cold in particular tends to decompose the phenol solutions known prior to the present invention, but by means of the present invention it is possible to obtain solutions which are clear and stable for prolonged periods of time even under the influence of light and cold, or changes of temperature.
  • compositions of the present invention possess remarkable therapeutic properties which cannot be accounted for or explained by reference to the known properties of the individual components,
  • the formulation has rubefacient, analgesic, penetrant, emollient and antiseptic properties.
  • it has the totally unexpected ability to bring about amelioration of the diseased conditions referred to above.
  • the therapeutic response is obtained not only when the composition is applied to the skin over the diseased area being treated, but also when the composition is applied to the skin over portions of the body other than that of the diseased area. While the mode of action of the composition is not understood, application of the composition apparently produces a systemic reaction. Beneficial effects are elicited at portions of the body distant from the site of application.
  • the compositions of the present invention are therefore unique and provide results which cannot be obtained in any other known way.
  • the invention is suitable for application to human beings, or to domesticated animals, for example, race horses having bowed tendons, jacks, splints, cunbs, arthritis and related conditions for which there is no fully satisfactory treatment known.
  • these conditions can be overcome successfully and painlessly.
  • the composition when a systemic reaction is desired as in the case of treatment for arthritis and related conditions, the composition is applied on the skin of the patient in the following manner. Application may be over the area of the body being treated, or it may be at another more convenient area. The area of the back is often convenient, and has the advantage of presenting a large surface.
  • the composition is applied, for example, to a wet-strength paper whose size and absorption carries a controlled amount of the composition, and the paper is spread over the skin. The composition is then smoothed the paper.
  • the hand is preferably shielded by a nonporous covering impervious to the formula, for example, a polyethylene glove or mitten.
  • the paper should preferably be non-woven.
  • a preferred embodiment of the present invention is a thin sheet of porous material which is uniformly impregnated with and holds the composition, generally by capillary action, and which is capable of being spread uniformly over the skin area to which application takes place.
  • the skin on which it has been applied becomes somewhat pink, but there is no more discomfort or injury than that resulting from a mild sunburn.
  • the treatment may be reapplied to the same area within three days.
  • Another important benefit of the present invention is in the treatment of tension headache.
  • the present composition results in the amelioration of this condition.
  • compositions are applied directly to the area being treated, generally by means of applications of varying sizes.
  • Application of the composition with the right pressure causes a controlled burn, which weeps and forms a crust. This crust cracks off, generally in eight days, and a new pink skin is found, which in a short while returns to its natural color. Beneath this skin is regenerated tissue.
  • the treatment requires approximately eight days.
  • the composition in a total amount approximating a fluid ounce, is applied with applicators on the entire face area in seven to ten minutes, resulting in a white localized reaction on the skin.
  • the localized reaction is like a severe sunburn, and causes a painless edema.
  • the skin weeps. some other antiseptic powder is applied as soon as the weeping begins, and it is applied whenever the liquid shows through the powder.
  • the patient is kept warm to increase the flow of liquid.
  • the treatment causes the formation of a thick crust, which shrinks as it dries, and presses against the face as the edema recedes.
  • compositions for systemic absorption are to slowly drip 2% cc. of the compositions on to the palms of the hands while they are rubbed together with the palms fiat and the fingers closed. When two or three drops are absorbed another two or three drops are dripped on the palms. This process is continued until the entire 2% cc. have been asbsonbed. This takes about seven minutes. While still rubbing the palms together cool water is run on them. The palms turn white but in about five minutes return to normal color. The compositions Thymol iodide powder or have thus entered the system and the local action has been neutralized.
  • composition of matter consisting essentially of the following substances in approximately the following proportions: 30 grams of phenol, 4 ml. of glycerine, 1 ml. of water, 0.1 to 0.5 gram of sodium salicylate and 0.1 to 0.5 gram of citric acid.
  • composition of matter consisting essentially of the following substances in aproximately the following proportions: 30 grams of phenol, 4 ml. of glycerine, 1 ml. of water, 0.3 gram of sodium salicylate and 0.3 gram of citric acid.
  • a process for the amelioration of a diseased ccndition characterized by inflammation of osseous, fibrous or cartilaginous connective tissue comprising applying to the skin of the diseased individual a composition consisting essentially of the following substances in approximately the following proportions: 30 grams of phenol, 4 ml. of glycerine, 1 ml. of water, 0.1 to 0.5 gram of sodium salicylate and 0.1 to 0.5 gram of citric acid.
  • a clear stable solution consisting essentially of the following substances in approximately the following proportions: 30 grams of phenol, 4 ml. of glycerine, 1 ml. of water, 0.1 to 0.5 gram of sodium salicylate and 0.1 to 0.5 gram of citric acid.
  • a clear stable solution consisting essentially of the following substances in approximately the following proportions: 30 grams of phenol, 4- ml. of glycerine, 1 ml. of water, 0.3 gram of sodium salicylate and 0.3 gram of citric acid.
  • An article of manufacture comprising a thin sheet of porous material uniformly impregnated with a composition consisting essentially of the following substances in approximately the following proportions: 30 grams of phenol, 4 ml. of glycerine, 1 ml. of water, 0.1 to 0.5 gram of sodium salicylate and 0.1 to 0.5 gram of citric acid.
  • An article of manufacture comprising a thin sheet of porous material uniformly impregnated with a composition consisting essentially of the following substances in approximately the following proportions: 30 grams of phenol, 4 ml. of glycerine, 1 ml. of Water, 0.3 gram of sodium salicylate and 0.3 gram of citric acid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US815276A 1959-05-25 1959-05-25 Therapeutic compositions Expired - Lifetime US3046196A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US815276A US3046196A (en) 1959-05-25 1959-05-25 Therapeutic compositions
FR828198A FR618M (en]) 1959-05-25 1960-08-31

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US815276A US3046196A (en) 1959-05-25 1959-05-25 Therapeutic compositions

Publications (1)

Publication Number Publication Date
US3046196A true US3046196A (en) 1962-07-24

Family

ID=25217346

Family Applications (1)

Application Number Title Priority Date Filing Date
US815276A Expired - Lifetime US3046196A (en) 1959-05-25 1959-05-25 Therapeutic compositions

Country Status (2)

Country Link
US (1) US3046196A (en])
FR (1) FR618M (en])

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210633A (en) * 1978-10-20 1980-07-01 Eli Lilly And Company Flurandrenolide film formulation
US4828912A (en) * 1981-07-20 1989-05-09 Kimberly-Clark Corporation Virucidal product having virucidal and/or germicidal properties
WO2002058688A1 (de) * 2001-01-24 2002-08-01 Mestex Ag Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen
US6475501B1 (en) 1997-06-04 2002-11-05 The Procter & Gamble Company Antiviral compositions for tissue paper
US6517849B1 (en) 1999-10-19 2003-02-11 The Procter & Gamble Company Tissue products containing antiviral agents which are mild to the skin
US20050100612A1 (en) * 2003-11-07 2005-05-12 Viratox, L.L.C. Virucidal activities of cetylpyridinium chloride
US20100144877A1 (en) * 2007-02-21 2010-06-10 Viratox, L.L.C. Synergistic Enhancement of Calcium Propionate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210633A (en) * 1978-10-20 1980-07-01 Eli Lilly And Company Flurandrenolide film formulation
US4828912A (en) * 1981-07-20 1989-05-09 Kimberly-Clark Corporation Virucidal product having virucidal and/or germicidal properties
US6475501B1 (en) 1997-06-04 2002-11-05 The Procter & Gamble Company Antiviral compositions for tissue paper
US6517849B1 (en) 1999-10-19 2003-02-11 The Procter & Gamble Company Tissue products containing antiviral agents which are mild to the skin
WO2002058688A1 (de) * 2001-01-24 2002-08-01 Mestex Ag Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen
US20040047807A1 (en) * 2001-01-24 2004-03-11 Dominik Meyer Use of neurotoxic substances in producing a medicament for treating joint pains
US20050100612A1 (en) * 2003-11-07 2005-05-12 Viratox, L.L.C. Virucidal activities of cetylpyridinium chloride
US20050100601A1 (en) * 2003-11-07 2005-05-12 Viratox, L.L.C. Virucidal activities of cetylpyridinium chloride
US20100144877A1 (en) * 2007-02-21 2010-06-10 Viratox, L.L.C. Synergistic Enhancement of Calcium Propionate
US8741954B2 (en) 2007-02-21 2014-06-03 Viratox, L.L.C. Synergistic enhancement of calcium propionate

Also Published As

Publication number Publication date
FR618M (en]) 1961-06-19

Similar Documents

Publication Publication Date Title
JP2004217675A (ja) 二酸化炭素含有粘性組成物
US3821370A (en) Topical composition for treating seborrheic keratosis
JPH0354086B2 (en])
JPS6026083B2 (ja) 皮膚美容用組成物
CZ117395A3 (en) Preparation containing extract from oak bark
US3046196A (en) Therapeutic compositions
US6391323B1 (en) Composition for the treatment of burns, sunburns, abrasions, ulcers and cutaneous irritation
US7141252B2 (en) Composition for the treatment of burns, sunburns, abrasions, ulcers and cutaneous irritation
CN108635253A (zh) 一种婴幼儿蛋黄油化妆品
RU2040252C1 (ru) Ранозаживляющее средство
US5973010A (en) Composition for healing skin wounds
US5616619A (en) Topical composition for burn relief and method of use
US3584129A (en) Preparation of a composition for the relief of arthritic pains
JPS6323968B2 (en])
KR101612463B1 (ko) 각질연화용 패치
US3825563A (en) Production of stable,nonhydrous,homogeneous,in natural and mineral oils soluble vitamin-e-active cream-base-co-esters of the mineral-oil-insoluble d-alpha-tocopheryl-acid-succinate with anhydrous oils
RU2062105C1 (ru) Мазь для лечения кожных заболеваний
RU2106150C1 (ru) Препарат для лечения ожогов кожи
US3098790A (en) Admixture of aluminum metal powder and powdered vegetable gum for treatment of open wounds
RU2135161C1 (ru) Композиция "рициниол" для лечения и косметического ухода за слизистыми оболочками, кожей и волосами
TWI290464B (en) Treatment of burns
RU2132193C1 (ru) Препарат для лечения и дезинфицирования кожи и слизистых оболочек
Lynch et al. The promotion of wound healing following chemosurgery (Mohs' technique) by dressings with a lotion of benzoyl peroxide
AU687840B2 (en) Topical composition for burn relief and method of use
JPS6256132B2 (en])